• 1
    Graf N,Tournade M-F,de Kraker J. The role of preoperative chemotherapy in the management of Wilms tumor. Urol Clin North Am. 2000; 27: 443-454.
  • 2
    Neville HL,Ritchey ML. Wilms tumor. Overview of National Wilms Tumor Study Group results. Urol Clin North Am. 2000; 27: 435-442.
  • 3
    Tournade MF,Com-Nouge C,de Krajer J, et al. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk adapted therapeutic approach in Wilms' tumor. J Clin Oncol. 1993; 11: 1014-1023.
  • 4
    de Kraker J,Delemarre JFM,Lilien MR,Tournade M-F. Misstaging in nephroblastoma. Causes and Consequences. A report of the sixth nephroblastoma trial and study of the International Society of Paediatric Oncology. Eur J Pediatr Surg. 1999; 9: 153-157.
  • 5
    Tournade MF,Com-Nougue C,de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumour in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' tumour trial and study. J Clin Oncol. 2001; 19: 488-500.
  • 6
    Boccon-Gibod L,Rey A,Sandstedt B, et al. Complete necrosis induced by preoperative chemotherapy in Wilms' tumor as an indicator of low risk: report of the International Society of Paediatric Oncology (SIOP) Wilms' tumor trial and study 9. Med Pediatr Oncol. 2000; 34: 183-190.
  • 7
    Weirich A,Leuschner I,Harms D, et al. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann Oncol. 2001; 12: 311-319.
  • 8
    de Kraker J,Graf N,van Tinteren H, et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trail. Lancet. 2004; 364: 1229-1235.
  • 9
    Mitchell C,Pritchard Jones K,Shannon R, et al. Immediate nephrectomy versus pre-operative chemotherapy in the management of non-metastatic Wilms' tumor: results of a randomized trial (UKWT3) by the UK Children's Cancer Study Group. Eur J Cancer. 2006; 42: 2554-2562.
  • 10
    SIOP 2001 Nephroblastoma Trial and Study Protocol, 2001.
  • 11
    SIOP 93-01 Nephroblastoma Trial and Study Protocol, 1993.
  • 12
    Dome JS,Cotton CA,Perlman EJ, et al. Treatment of anaplastic Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol. 2006; 24: 2352-2358.
  • 13
    Qualman SJ,Coffin CM,Newton WA, et al. Intergroup rhabdomyosarcoma study: update for pathologists. Pediatr Dev Pathol 1998; 1: 550-561.
  • 14
    Parkers SE,Muir KR,Cameron AH, et al. The need for specialist review of pathology in paediatric cancer. Br J Cancer. 1997; 75: 1156-1159.
  • 15
    Delaney RJ,Sayers CD,Walker MA,Mead GM,Theaker JM. The continued value of central histopathology review of testicular tumours. Histopathology. 2005; 47: 166-169.
  • 16
    Scott CB,Nelson JS,Farnan NC, et al. Central Pathology Review in clinical trials for patients with malignant glioma. A report of Radiation Therapy Oncology Group 83-02. Cancer. 1995; 76: 307-313.
  • 17
    Van Dijk MC,Aben KK,van Hees F, et al. Expert review remains important in the histopathological diagnosis of cutaneous melanocytic lesions. Histopathology. 2008; 52: 139-416.
  • 18
    Van der Kwast TH,Collette L,Van Poppel, et al. Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). Virchows Arch. 2006; 449: 428-434.
  • 19
    Furness P. Guidelines on Inter-departmental Dispatch of Samples From Patients Sent to Another Hospital or Centre for Assessment and/or Treatment. 2nd ed. London, UK: The Royal College of Pathologists; 2006.
  • 20
    Teot LA,Sposto R,Khayat A,Qualman S,Reaman G,Parham D. The problems and promise of central pathology review: development of a standardized procedure for the Children's Oncology Group. Pediatr Dev Pathol. 2007; 10: 199-207.